Previous 10 | Next 10 |
Gainers: Creative Realities (NASDAQ:CREX) +128%. Casper Sleep (NYSE:CSPR) +86%. Siyata Mobile (NASDAQ:SYTA) +33%. Patriot National Bancorp (NASDAQ:PNBK) +35%. SilverSun Technologies (NASDAQ:SSNT) +26%. The Vita CoCo (NASDAQ:COCO) +24%. Trio-Tech (NYSE:TRT) +24%. Gores Guggenheim (NASDAQ:GGPI)...
UroGen Pharma (NASDAQ:URGN): Q3 GAAP EPS of -$1.35 misses by $0.06. Revenue of $11.35M (+228.0% Y/Y) misses by $4.07M. Press Release For further details see: UroGen Pharma EPS misses by $0.06, misses on revenue
Shift to single-arm Phase 3 study for UGN-102 in bladder cancer streamlines pivotal study to form basis of FDA submission Jelmyto® net product revenue of $11.4 million for the third quarter of 2021; New patient starts in September and October outpace July and August by ...
UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat urothelial and specialty cancers, today announced that it will present at the following virtual healthcare conferences in November: Stifel 2021 Virtual...
New, Single-arm Phase 3 Study Expected to Initiate in Early 2022 UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat urothelial and specialty cancers, is announcing at its virtual Spotlight E...
Program to Highlight UGN-102 and Company’s Innovative Early-stage Pipeline Programs Company to Report Third Quarter 2021 Financial Results on November 15, 2021 UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and com...
Clinically Meaningful Response and Sustained Durability Underscore Potential for UGN-102 to Become a Non-Surgical Primary Therapeutic Treatment for Patients with Highly Recurrent LG IR-NMIBC 65% Complete Response (CR) Rate at Three Months 61% of Patients Remain in CR...
UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that it will present at the Cantor Fitzgerald 2021 Virtual Global Healthcare Conference on Thursda...
Final data from Phase 2b OPTIMA II trial of UGN-102 showed complete and durable response for intravesical instillation in patients with low-grade intermediate risk NMIBC Long-term data from pivotal OLYMPUS trial underscores durable benefit of Jelmyto ® for adult pat...
UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that it will present at the H.C. Wainwright 23 rd Annual Global Investment Conference. The pre...
News, Short Squeeze, Breakout and More Instantly...
2024-06-25 07:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the pricing of an underwritten public offering of 5,000,000 ordinary shares at a price to the public of $17.50 per ord...
PRINCETON, N.J., June 17, 2024 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it has commenced an underwritten public offering, subject to m...